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XIAP blocks the apoptosis by binding to and inhibiting caspases-3, -7 and -9. XIAP 
is negatively regulated by the mitochondrial serine protease HtrA2/Omi. The aim 
of this study was to investigate the role of XIAP and the relationship between XIAP 
and HtrA2/Omi in patients with Parkinson’s disease or dementia with Lewy bodies. 
We performed immunohistochemical studies on XIAP in formalin-fixed, paraffin- 
embedded sections from 8 normal subjects, 10 patients with Parkinson’s disease, 5 
patients with dementia with Lewy bodies and 7 patients with Alzheimer’s disease, 
and then double-labeling immunohistochemistry for XIAP and HtrA2/Omi in 
sections from the Parkinson’s disease and dementia with Lewy bodies cases. 
Brainstem-type and cortical Lewy bodies were intensely immunostained for XIAP, 
and XIAP immunoreactivity was localized to the halos of brainstem-type Lewy 
bodies and to the entire bodies of cortical Lewy bodies. Double 
immunofluorescence analyses showed that XIAP and HtrA2/Omi 
immunoreactivities were co-localized to both types of Lewy bodies. Our results 
suggest that XIAP may be partially associated with the pathogenesis of Parkinson’s 
disease and dementia with Lewy bodies. 
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Introduction 
The inhibitor of apoptosis protein (IAP) family members have been widely conserved in 
a large number of eukaryotic species, ranging from insects to humans, and play an 
important role in regulating apoptotic cell death [1]. The IAP family of proteins is 
characterized by a novel domain of about 70 amino acids termed the baculovirus IAP 
repeat (BIR), the name of which derives from the original discovery of IAP family 
proteins in baculoviruses [1,2]. X-linked IAP (XIAP), a member of the IAP family, has 
the ability to directly bind to and inhibit the initiator caspase-9, and the effectors 
caspase-3 and caspase-7, thus blocking the apoptotic process [3,4]. XIAP contains three 
tandem BIR domains [1,2,4], and the caspase-3 and -7 inhibitory functions of XIAP 
were demonstrated to be localized to the second BIR domain [5], whereas the third BIR 
domain of XIAP was shown to be sufficient for inhibiting caspase-9 activity [6]. These 
data suggest that the three BIR domains within XIAP may have distinct functions, and 
that XIAP may inhibit the initiator and effector caspases in a different manner. 
 
XIAP is negatively regulated by several proteins, including the mitochondrial serine 
protease HtrA2/Omi [7-10], which is released from the mitochondria into the cytosol 
upon receiving various apoptotic stimuli [7-10]. HtrA2/Omi binds to XIAP and blocks 
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its caspase-inhibitory activities [7-10]. Recently, we reported the immunohistochemical 
localization of HtrA2/Omi in brainstem-type and cortical Lewy bodies from brains with 
Parkinson’s disease or dementia with Lewy bodies [11]. In the present study, we 
performed immunohistochemical studies on XIAP and HtrA2/Omi using autopsied 
brains with Parkinson’s disease or dementia with Lewy bodies, and found that 
brainstem-type and cortical Lewy bodies were intensely immunostained for XIAP, and 
that the XIAP and HtrA2/Omi immunoreactivities were co-localized to both types of 
Lewy bodies. 
 
Materials and methods 
Tissue preparation  
We studied autopsied brains from 8 control subjects without any neurological 
abnormalities (age range, 54-78 years; mean, 68.4 years; 6 men and 2 women), 10 
patients with Parkinson’s disease (age range, 66-90 years; mean, 77.5 years; 6 men and 
4 women) and 5 patients with dementia with Lewy bodies (age range, 69-86 years; 
mean, 74.8 years; 4 men and 1 woman). Autopsied brains from 7 patients with 
Alzheimer’s disease (age range, 67-89 years; mean, 78.4 years; 2 men and 5 women) 
served as disease controls. All brains were fixed in 10% neutral formalin for about 2 
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weeks at room temperature. Several paraffin-embedded tissue blocks, including the 
frontal and temporal cortices, midbrain and upper pons, were prepared and cut into 6- 
μm-thick sections on a microtome. The paraffin-embedded sections were deparaffinized 
in xylene, and then followed by rehydration in a decreasing concentration of ethanol 
solutions. For routine pathological evaluation, deparaffinized sections from all cases 
were stained with the hematoxylin and eosin (H&E), Klüver-Barrera and modified 
Bielschowsky methods. The use of human materials was in agreement with the ethical 
guidelines set forth by Kyoto University. 
 
Immunohistochemistry 
To examine the immunohistochemical localization of XIAP in normal and diseased 
brains, we used a goat polyclonal anti-XIAP antibody (AF8221, R&D systems, 
Minneapolis, MN, USA). The deparaffinized sections were pretreated with 0.3% 
hydrogen peroxide (Santoku, Tokyo, Japan) in 0.1 M phosphate-buffered saline (PBS) 
for 30 min at room temperature to inhibit endogenous peroxidase activity. After washing 
with 0.1 M PBS, the sections were blocked with 0.1 M PBS with 3% skim milk for 2 h 
at room temperature. After rinsing with 0.1 M PBS, the anti-XIAP antibody diluted in 
0.1 M PBS (15 μg/ml) was applied onto the sections, and the sections were incubated at 
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4°C overnight in a humidified chamber. After washing with 0.1 M PBS, the sections 
were reacted with a biotinylated anti-goat IgG (Vector Laboratories, Burlingame, CA, 
USA) diluted in 0.1 M PBS (1:200) for 1 h at room temperature, and then followed by 
incubation with an avidin-biotin-peroxidase complex (ABC) kit (Vector Laboratories) 
diluted in 0.1 M PBS (1:400) for 1 h at room temperature. After rinsing with 0.1 M PBS 
and then in 0.05 M Tris-HCl (pH 7.6), the sections were developed in a colorizing 
solution containing 0.02% diaminobenzidine tetrahydrochloride (Dojin, Kumamoto, 
Japan), 0.6% ammonium nickel (II) sulfate (Wako, Osaka, Japan) and 0.005% hydrogen 
peroxide in 0.05 M Tris-HCl (pH 7.6) for 10 min at room temperature. Some H&E- 
stained sections with brainstem-type or cortical Lewy bodies were color-photographed, 
decolorized with 70% ethanol, and were then immunostained with the anti-XIAP 
antibody using the ABC method described above. As a negative immunohistochemical 
control, some sections were incubated with normal goat serum, and no specific 
immunopositive staining was detected in these control sections (data not shown). 
 
Double immunofluorescence staining 
To compare the anatomical distribution of XIAP-immunoreactive Lewy bodies to that 
of HtrA2/Omi-positive Lewy bodies in brains with Parkinson’s disease or dementia with 
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Lewy bodies, we performed double-labeling immunohistochemistry using the anti- 
XIAP antibody and an anti-HtrA2/Omi antiserum, which was raised by immunizing 
rabbits with E coli expressing the C-terminal His6-tagged mature form of the human 
HtrA2/Omi protein [7]. Sections from all of the Parkinson’s disease and dementia with 
Lewy bodies cases were incubated with a combination of the anti-XIAP antibody (15 
μg/ml) plus the anti-HtrA2/Omi antiserum (1:200) in 0.1 M PBS at 4°C overnight. After 
washing with 0.01 M PBS, the sections were reacted with secondary antibodies 
consisting of a fluorescein isothiocyanate-conjugated swine anti-goat IgG (Biosource, 
Camarillo, CA, USA) and a tetramethylrhodamine-conjugated swine anti-rabbit IgG 
(DakoCytomation, Glostrup, Denmark). After rinsing with 0.01 M PBS, the slides were 
coverslipped with Vectashield (Vector Laboratories), and were then viewed with a 
fluorescence microscope system (BZ-9000, Keyence, Osaka, Japan). 
 
Semiquantitative assessment of Lewy bodies immunostained for XIAP and HtrA2/ 
Omi 
To evaluate the proportions of Lewy bodies which were immunoreactive for both XIAP 
and HtrA2/Omi, we prepared H&E-stained sections from all of the Parkinson’s disease 
and dementia with Lewy bodies cases. After counting the number of brainstem-type 
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Lewy bodies in the substantia nigra and locus ceruleus in Parkinson’s disease and the 
number of cortical Lewy bodies in the cingulate and parahippocampal cortices in 
dementia with Lewy bodies, these sections were decolorized with 70% ethanol, and 
were then double-immunostained for XIAP and HtrA2/Omi. After counting the number 
of double-immunolabeled Lewy bodies in the same areas, we calculated the percentage 
of double-immunolabeled Lewy bodies in each section, and then calculated the average 
percentages of brainstem-type Lewy bodies in the substantia nigra and locus ceruleus 
and the average percentages of cortical Lewy bodies in the cingulate and 
parahippocampal cortices.  
 
Results 
XIAP immunoreactivity in normal and diseased brains  
In the frontal and temporal cortices from control subjects, both pyramidal and non- 
pyramidal neurons were immunostained for XIAP at various degrees of intensity (Fig. 
1a). Granular XIAP immunoreactive products accumulated in the somata and proximal 
processes of some neurons (Fig. 1b). In the frontal and temporal white matter from the 
control subjects, XIAP-immunopositive glial cells were scattered throughout (Fig. 1c), 
some of which were oligodendrocytes by morphology (Fig. 1d). These neuronal and 
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glial immunolabeling patterns suggest that XIAP may be partially activated even in the 
normal brains.  
 
In the substantia nigra and locus ceruleus from normal controls, about 60% of the 
pigmented neurons were mildly immunostained for XIAP, and the rest were moderately 
immunostained (Fig. 1e). In the same areas from patients with Parkinson’s disease or 
dementia with Lewy bodies, a similar immunolabeling pattern was observed, and XIAP 
immunoreactivity was spared in the remaining neurons (Fig. 1f). 
 
XIAP immunoreactivity in brainstem-type and cortical Lewy bodies 
Brainstem-type Lewy bodies, which consist of an eosinophilic core plus a surrounding 
pale halo (Fig. 2a), showed a ring-shaped XIAP-immunolabeling pattern, and the halos 
of these Lewy bodies were intensely immunostained (Fig. 2b). Some remaining neurons 
contained two or more brainstem-type Lewy bodies (Fig. 2c), and the marginal rims of 
these Lewy bodies were strongly immunoreactive for XIAP (Fig. 2d).  
 
Cortical Lewy bodies, which are poorly-defined, eosinophilic structures without a clear 
halo (Fig. 2e and g), were intensely immunostained for XIAP (Fig. 2f and h). XIAP 
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immunoreactivity was localized over the entire bodies of these Lewy bodies (Fig. 2f and 
h). 
 
Double-labeling immunohistichemstry for HtrA2/Omi and XIAP 
The double-immunostained sections of the midbrain and upper pons from patients with 
Parkinson’s disease revealed the immunohistochemical co-localization of HtrA2/Omi 
and XIAP in brainstem-type Lewy bodies (Fig. 3a-c). The co-immunoexpression of both 
proteins was detected in the halos of these Lewy bodies (Fig. 3a-c). The average 
percentages of double-immunolabeled brainstem-type Lewy bodies in the substantia 
nigra and locus ceruleus were 67.5% and 58.8%, respectively.  
 
The double-immunostained sections of the frontal and temporal cortices from patients 
with dementia with Lewy bodies revealed the immunohistochemical co-localization of 
HtrA2/Omi and XIAP in cortical Lewy bodies (Fig. 3d-f). The co-immunoexpression of 
both proteins was detected in the entire bodies of these Lewy bodies (Fig. 3d-f). The 
average percentages of double-immunolabeled cortical Lewy bodies in the cingulate and 
parahippocampal cortices were 56.6% and 68.4%, respectively. 
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XIAP immunoreactivity in brains with Alzheimer’s disease 
In the frontal and temporal cortices from patients with Alzheimer’s disease, many 
XIAP-immunoreactive senile plaques were distributed (Fig. 4a), and strong XIAP 
immunoreactivity was observed in the cores of some senile plaques (Fig. 4b). These 
immunostaining patterns were similar to those of HtrA2/Omi in brains with Alzheimer’s 
disease [12], and our results indicate that neither XIAP nor HtrA2/Omi accumulate 
specifically in brainstem-type and cortical Lewy bodies. 
 
Discussion 
Strauss and colleagues initially reported missense mutations in the gene encoding 
HtrA2/Omi in some patients with sporadic Parkinson’s disease [13]. They also 
described the immunohistochemical localization of XIAP to brainstem-type Lewy 
bodies in autopsied brains with Parkinson’s disease, but the immunohistochemical data 
on XIAP were not shown in their paper [13]. In accordance with their results, we 
observed that brainstem-type Lewy bodies were intensely immunostained for XIAP. In 
addition to brainstem-type Lewy bodies, we also observed that cortical Lewy bodies 
were strongly immunoreactive for XIAP. Furthermore, we observed the co-localization 
of XIAP and HtrA2/Omi immunoreactivities in the brainstem-type and cortical Lewy 
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bodies. To our best knowledge, this is the first report that documents the 
immunohistochemical localization of XIAP not only in brainstem-type Lewy bodies, but 
also in cortical Lewy bodies, and the co-immunoexpression of XIAP and HtrA2/Omi in 
both types of Lewy bodies. 
 
In the present study, we demonstrated that XIAP immunoreactivity was localized to the 
halos of brainstem-type Lewy bodies and to the entire bodies of cortical Lewy bodies. 
These immunolabeling patterns were similar to those of HtrA2/Omi in brains with 
Parkinson’s disease or dementia with Lewy bodies [11]. Our double- 
immunohistochemical studies revealed the co-localization of XIAP and HtrA2/Omi 
immunoreactivities in both types of Lewy bodies. HtrA2/Omi is released from the 
mitochondrial intermembrane space into the cytosol upon receiving various apoptotic 
stimuli, and this released HtrA2/Omi induces apoptotic cell death by binding to various 
IAPs, including XIAP, and blocking their caspase-inhibitory activities [7-10]. Since the 
interaction between HtrA2/Omi and XIAP occurs in the extra-mitochondrial areas, 
intra-mitochondrial HtrA2/Omi is not able to interact with XIAP in normal appearing 
neurons, but our results suggest that HtrA2/Omi may be released from the mitochondria 
into the cytosol in Lewy body-containing neurons, and that this extra-mitochondrial 
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HtrA2/Omi may make a partial contribution to neuronal cell death in brains with 
Parkinson’s disease and dementia with Lewy bodies.  
 
The striatal administration of adenovirus-mediated XIAP and glial cell line-derived 
neurotrophic factor was demonstrated to have synergistic effects for rescuing midbrain 
dopaminergic neurons from cell death, and for maintaining the nigrostriatal terminals in 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models of Parkinson’s 
disease [14]. The neuronal overexpression of XIAP was also shown to attenuate MPTP- 
induced dopaminergic neuronal degeneration in the substantia nigra using XIAP 
transgenic mice under the control of the neuron-specific enolase promoter [15]. These 
data suggest that XIAP may play an important role in protecting nigral dopaminergic 
neurons in brains affected by Parkinson’s disease. On the other hand, activated caspase- 
3 immunoreactivity was reported to be increased in the substantia nigra from patients 
with Parkinson’s disease [16,17]. Using the TdT-mediated dUTP-biotin nick-end 
labeling (TUNEL) method, Mochizuki and coworkers showed that some dopaminergic 
neurons were TUNEL-positive in the substantia from patients with Parkinson’s disease, 
and suggested that apoptosis may be associated with dopaminergic neuronal death in 
patients with Parkinson’s disease [18]. In the present study, we observed the 
Y. Kawamoto et al. 15 
 
localization of XIAP immunoreactivity in the brainstem-type Lewy bodies in the 
substantia nigra from patients with Parkinson’s disease. Our findings suggest that the 
sequestration of XIAP into the brainstem-type Lewy bodies may suppress the anti- 
apoptotic function of XIAP, and that this dysfunction of XIAP may partially contribute 
to apoptotic cell death in the substantia nigra affected by Parkinson’s disease.  
 
Conclusion 
In this study, we demonstrated that XIAP immunoreactivity densely accumulated in the 
brainstem-type and cortical Lewy bodies in brains with Parkinson’s disease or dementia 
with Lewy bodies, and our results suggest that XIAP may be partially associated with 
the pathogenesis of these Lewy body-related diseases. 
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Figure 1. XIAP immunoreactivity in the frontal cerebral cortex (a, b) and white matter 
(c, d) from normal subjects. Both neurons (a, b) and glial cells (c, d) were 
immunostained for XIAP. XIAP immunoreactivity in the substantia nigra from control 
(e) and Parkinson’s disease (f) cases. The somata and processes of the pigmented 
neurons were immunoreactive for XIAP in both cases (e, f). Scale bars = 50 μm (a, c), 
20 μm (b, d) and 100 μm (e, f). 
 
Figure 2. Midbrain sections stained with H&E (a, c) and immunostained for XIAP (b, 
d). Brainstem-type Lewy bodies are eosinophilic structures with a central core and a 
peripheral halo (a, c), and the halos of these Lewy bodies were intensely immunostained 
for XIAP (b, d). As indicated by the arrows, the Lewy bodies in (a) and (c) were 
identical to those in (b) and (d), respectively. Frontal cortical sections stained with H&E 
(e, g) and immunostained for XIAP (f, h). Cortical Lewy bodies, which are 
homogeneously eosinophilic structures without a clear halo (e, g), were intensely 
immunostained for XIAP (f, h). As indicated by the arrows, the Lewy bodies in (e) and 
(g) were identical to those in (f) and (h), respectively. Scale bars = 20 μm (a-h). 
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Figure 3. Double-immunofluorescence staining for HtrA2/Omi (a) and XIAP (b) in the 
substantia nigra from patients with Parkinson’s disease. The merged images showed that 
the HtrA2/Omi and XIAP immunoreactivities were co-localized to the brainstem-type 
Lewy bodies (c). The arrows in (a) to (c) indicate the same Lewy bodies. Double- 
immunofluorescence staining for HtrA2/Omi (d) and XIAP (e) in the frontal cortex 
from patients with dementia with Lewy bodies. The merged images showed that the 
HtrA2/Omi and XIAP immunoreactivities were co-localized to the cortical Lewy bodies 
(f). The arrows in (d) to (f) indicate the same Lewy bodies. Scale bars = 20 μm (a-f). 
 
Figure 4. XIAP immunoreactivity in the frontal cortex from patients with Alzheimer’s 
disease. Many senile plaques were immunoreactive for XIAP (a), and strong XIAP 
immunoreactivity was found in the cores of some senile plaques (b, arrow). Scale bars = 
40 μm (a) and 20 μm (b). 
 
